The suspension is a temporary positive as it removes immediate ATM overhang, but the company still needs capital and faces deep operating losses. Monitor for any new financing announcements or further dilution restructuring. The stock is highly volatile and fundamentals remain weak.
Price Chart
Executive Summary
AIM ImmunoTech filed a 424B5 to suspend its equity distribution agreement (ATM) with Maxim Group, halting further sales under the current shelf. The suspension removes near-term dilution overhang, but the company has already sold $2.85M of the $3.41M registered, and a simultaneous 8-K revealed a Q1 EPS miss (-$0.57 vs -$0.37) and ongoing financial distress for this $3M market cap micro-cap.
Key Facts
- Suspends sales under the Equity Distribution Agreement; no further ATM sales until a new prospectus supplement is filed.
- As of May 19, 2026, $2,847,151.09 of common stock had been sold under the EDA (out of $3,409,174 registered).
- Stock price was $0.4080 per share on May 18, 2026.
- 8-K filed same day reports debt extension with Streeterville to June 2027, improved equity ($2.1M vs -$9.8M deficit), and Q1 EPS miss.
- Market cap is approximately $3M, indicating extreme micro-cap risk.
Financial Impact
Removes potential future dilution of up to ~$562k (remaining registered amount). Already sold $2.85M, which is substantial relative to market cap.
Risk Factors
- Further capital needs may force dilutive financing at low prices.
- Debt with Streeterville (amended again) suggests ongoing liquidity pressure.
- Low cash runway and negative earnings per share persist.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-024458 |
| Document: 0001493152-26-024458-index-headers.html | 0001493152-26-024458 |
| Document: 0001493152-26-024458-index.html | 0001493152-26-024458 |
| Document: 0001493152-26-024458.txt | 0001493152-26-024458 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers